keyword
MENU ▼
Read by QxMD icon Read
search

Uveitic macular edema

keyword
https://www.readbyqxmd.com/read/29580977/difluprednate-for-the-treatment-of-uveitic-cystoid-macular-edema
#1
Julie M Schallhorn, Katherine M Niemeyer, Erica N Browne, Parth Chhetri, Nisha R Acharya
PURPOSE: To describe clinical outcomes associated with the use of topical difluprednate in treating uveitic cystoid macular edema. DESIGN: Retrospective, interventional case series. METHODS: Setting: Medical record review in a tertiary care uveitis center. PATIENT POPULATION: 58 patients (72 eyes) with uveitic cystoid macular edema (CME) treated with difluprednate 0.05% ophthalmic solution between June 2012 and May 2016...
March 23, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29394119/safety-and-efficacy-of-intravitreal-dexamethasone-implant-for-refractory-uveitic-macular-edema-in-adults-and-children
#2
Dhanashree Ratra, Atanu Barh, Manideepa Banerjee, Vineet Ratra, Jyotirmay Biswas
PURPOSE: To assess safety and efficacy of intravitreal dexamethasone (DEX) implant in refractory uveitic macular edema (ME). METHODS: We retrospectively analyzed medical records of patients with nonresponsive ME secondary to chronic, noninfectious intermediate or posterior uveitis, treated with intravitreal DEX implants. RESULTS: A total of 42 eyes of 34 patients (aged 6-67 years) received 56 implants. Mean follow-up was 19.2 ± 2.2 months after DEX implant...
February 2, 2018: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/29346240/response-of-inflammatory-cystoid-macular-edema-to-treatment-using-oral-acetazolamide
#3
Kathryn L Pepple, Macklin H Nguyen, Kaivon Pakzad-Vaezi, Kathleen Williamson, Naomi Odell, Cecilia Lee, Thellea K Leveque, Russell N Van Gelder
PURPOSE: To determine the treatment effect of oral acetazolamide on refractory inflammatory macular edema. METHODS: A retrospective review of identified patients with uveitic or pseudophakic macular edema treated using acetazolamide between 2007 and 2014. Visual acuity and central macular subfield thickness was determined at baseline and at first follow-up. Baseline optical coherence tomography features were analyzed as predictors of acetazolamide response. RESULTS: Sixteen patients (19 eyes) of 61 screened met all criteria...
January 16, 2018: Retina
https://www.readbyqxmd.com/read/29208813/decision-making-and-management-of-uveitic-cataract
#4
REVIEW
Nicole Shu-Wen Chan, Seng-Ei Ti, Soon-Phaik Chee
The visual outcome of uveitic cataract surgery depends on the underlying uveitic diagnosis, the presence of vision-limiting pathology and perioperative optimization of disease control. A comprehensive preoperative ophthalmic assessment for the presence of concomitant ocular pathology, with particular emphasis on macula and optic nerve involvement, is essential to determine which patients will benefit from improved vision after cataract surgery. Meticulous examination in conjunction with adjunct investigations can help in preoperative surgical planning and in determining the need for combined or staged procedures...
December 2017: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/29184384/treatment-of-refractory-uveitic-macular-edema-results-of-a-first-and-second-implant-of-long-acting-intravitreal-dexamethasone
#5
Marta Zola, Cristina Briamonte, Umberto Lorenzi, Federica Machetta, Federico M Grignolo, Antonio M Fea
Purpose: The purpose of this study was to report the functional and anatomical outcomes of a prospective study resulting from repeated dexamethasone intravitreal implants in patients with uveitic refractory macular edema. Methods: Twelve eyes of 9 patients with intermediate and posterior noninfectious inflammatory uveitis complicated with refractory macular edema were regularly reviewed after a dexamethasone intravitreal implant. Patients were examined at baseline, 30, 90, 135, and 180 days with best-corrected visual acuity (BCVA), complete slit-lamp examination, intraocular pressure (IOP), optical coherence tomography, and fluorescein angiography...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29157128/twenty-four-months-follow-up-of-intravitreal-bevacizumab-injection-versus-intravitreal-triamcinolone-acetonide-injection-for-the-management-of-persistent-non-infectious-uveitic-cystoid-macular-edema
#6
Andrés F Lasave, Ariel Schlaen, David G Zeballos, Manuel Díaz-Llopis, Cristóbal Couto, Wael M El-Haig, J Fernando Arevalo
PURPOSE: To report the efficacy of intravitreal bevacizumab (IVB) injection versus intravitreal triamcinolone acetonide (IVT) for persistent non-infectious uveitic cystoid macular edema (CME). METHODS: Interventional retrospective comparative case series evaluated 37 consecutive patients (44 eyes) with completely controlled uveitis and recalcitrant CME. Patients received repeated injections of 1.25 mg of IVB or 4 mg of IVT. RESULTS: Best-corrected visual acuity (BCVA) at baseline and 24 months was logMAR 1 and 0...
November 20, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28755068/-intravitreal-methotrexate-for-treatment-of-uveitic-cystoid-macular-edema
#7
J Maaß, E Matthé
We present the case of a patient who had several intravitreal methotrexate injections due to a uveitic macular edema and a known steroid response. An earlier off-label therapy with avastin had not been successful. After the intravitreal methotrexate injections a good resorption of the retinal fluid as well as a good intraocular pressure and a good visual acuity could be achieved. Visual acuity was limited by pre-existing glaucomatous optic nerve atrophy and a central scar in the cornea.
July 28, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28557602/systemic-steroid-sparing-effect-of-intravitreal-dexamethasone-implant-in-chronic-noninfectious-uveitic-macular-edema
#8
Claudia Fabiani, Antonio Vitale, Giacomo Emmi, Giuseppe Lopalco, Lorenzo Vannozzi, Daniela Bacherini, Silvana Guerriero, Rosa Anna Favale, Fiorella Fusco, Rossella Franceschini, Bruno Frediani, Florenzo Iannone, Mauro Galeazzi, Gian Marco Tosi, Luca Cantarini
PURPOSE: To evaluate the effectiveness and the systemic corticosteroid sparing effect of a single intravitreal dexamethasone (DEX) implant in patients with chronic noninfectious uveitic macular edema (UME). METHODS: Data from 22 eyes treated with DEX implant for UME related to systemic or ocular-confined noninfectious diseases were retrospectively analyzed. RESULTS: The mean systemic prednisone (or equivalent) dosage significantly decreased at 3- and 6-month follow-up evaluations compared to baseline (P = 0...
September 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28419393/role-of-disorganization-of-retinal-inner-layers-as-an-optical-coherence-tomography-biomarker-in-diabetic-and-uveitic-macular-edema
#9
Dilraj S Grewal, Seenu M Hariprasad, Glenn J Jaffe
No abstract text is available yet for this article.
April 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28351051/insights-into-the-physiopathology-of-inflammatory-macular-edema
#10
REVIEW
Marc D de Smet
Macular edema is one of the most common causes of permanent vision loss in patients with uveitis. The current understanding of water balance and metabolism within the retina has given us better insight into the mechanisms underlying macular edema arising from both acute and chronic inflammation. Uveitic macular edema (UME) occurs when the equilibrium between water influx and efflux is lost, and more importantly when compensatory mechanisms are overwhelmed. While in the acute setting, control of inflammation can reestablish homeostasis, chronic inflammation can lead to alternate pathways to establish a water balance...
2017: Developments in Ophthalmology
https://www.readbyqxmd.com/read/28237411/association-of-disorganization-of-retinal-inner-layers-with-visual-acuity-in-eyes-with-uveitic-cystoid-macular-edema
#11
RANDOMIZED CONTROLLED TRIAL
Dilraj S Grewal, Matthew L O'Sullivan, Martina Kron, Glenn J Jaffe
PURPOSE: To determine whether disorganization of retinal inner layers (DRIL) assessed by spectral-domain optical coherence tomography (SDOCT) correlates with visual acuity (VA) in eyes with uveitic cystoid macular edema (CME). DESIGN: Secondary analysis of randomized clinical trial data. METHODS: Fifty-six eyes of 42 patients with uveitic CME were prospectively imaged as part of the VISUAL-1 trial (Clinicaltrials.gov identifier NCT01138657)...
May 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28165851/intravitreal-antiangiogenic-therapy-of-uveitic-macular-edema-a-review
#12
REVIEW
Igor Kozak, Samir S Shoughy, Donald U Stone
Uveitic (or inflammatory) macular edema (UME) is one of the most common cause of visual impairment in patients with uveitis and the most frequent structural complication of uveitis. The use of antiangiogenic agents in the management of macular edema due to inflammation is a fairly new approach. It is not entirely clear if these agents should be used as an adjunct to anti-inflammatory therapy or if they can be used as stand-alone agents in edema due to infections where immunosuppressive therapy could be detrimental to the resolution of infection...
May 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28127443/the-unusual-association-of-inverse-retinitis-pigmentosa-and-fuchs-heterochromic-iridocyclitis
#13
Gian Franco Díez-Cattini, David Arturo Ancona-Lezama, Carlos Valdés-Lara, Virgilio Morales-Cantón
BACKGROUND: Classic retinitis pigmentosa (RP) and other syndromic variants have previously been associated to Fuchs' heterochromic iridocyclitis (FHI). Common immunogenic and inflammatory pathways have been proposed to explain the higher incidence of this uveitic phenomenon in patients with retinal dystrophies without definitive answers. Infrequent variants of RP such as inverse RP have not been previously reported in association with FHI. We believe that finding the way these entities connect can shed some light into their complex pathogenesis and help find ways to foresee and prevent the appearance of complications such as cataract and macular edema...
2017: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/28112568/vitrectomy-for-epiretinal-membranes-and-macular-holes-in-uveitis-patients
#14
REVIEW
Sara V Branson, Brendan R McClafferty, Shree K Kurup
PURPOSE: Macular pathology, including macular holes (MHs), epiretinal membranes (ERMs), and macular edema, is a cause of irreversible vision loss in the setting of uveitis. Medical management involves corticosteroids, immunomodulatory medications, and biologics to control inflammation. Pars plana vitrectomy (PPV) has been suggested as a therapy for uveitis, with reports of reduced inflammation and decreased dependence on medication postoperatively. Currently, PPV is reserved for retinal detachments, vitreous opacities, and ERMs, causing vitreomacular traction...
May 2017: Journal of Ocular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28080174/the-use-of-topical-non-steroidal-anti-inflammatory-drugs-for-uveitic-cystoid-macular-edema
#15
Harry Petrushkin, Duncan Rogers, Carlos Pavesio
The use of topical non-steroidal anti-inflammatory drugs in the management of uveitic cystoid macular edema is controversial. In this letter, we review the literature and report our results from a retrospective case series of 281 patients taking topical nepafenac 0.1% for uveitic cystoid macular edema between 2010 and 2016. Over a 4-month period, there was a modest improvement in best-corrected visual acuity (0.66 ± 3.7 logMAR) and central macular thickness (69.8 ± 132.5 μm). Patients with idiopathic anterior uveitis and HLA-B*27-associated anterior uveitis recovered more vision while taking topical nepafenac 0...
January 12, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28043984/cataract-surgery-in-uveitis-a-multicentre-database-study
#16
MULTICENTER STUDY
Colin J Chu, Andrew D Dick, Robert L Johnston, Yit C Yang, Alastair K Denniston
BACKGROUND/AIMS: Cataract is an important source of visual loss in patients with uveitis. Whether or not outcomes of cataract surgery in eyes with uveitis are worse compared with non-uveitic eyes have to date been compromised by lack of reliable estimates of benefit and harm, which require data from large cohorts. METHODS: Electronic medical record data were extracted from eight independent UK clinical sites for eyes undergoing cataract extraction between January 2010 and December 2014...
August 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/27893624/prospective-evaluation-of-a-sustained-release-dexamethasone-intravitreal-implant-for-cystoid-macular-edema-in-quiescent-uveitis
#17
Rahul N Khurana, Alok S Bansal, Louis K Chang, James D Palmer, Chengqing Wu, Mark R Wieland
PURPOSE: To investigate dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc) in the treatment of uveitic cystoid macular edema that had persisted in the absence of intraocular inflammation. METHODS: In this prospective interventional case series, 10 patients with uveitic cystoid macular edema and quiescent uveitis were treated with dexamethasone intravitreal implant at baseline and evaluated monthly for one year. Patients were retreated whenever cystoid macular edema recurred...
September 2017: Retina
https://www.readbyqxmd.com/read/27736275/iluvien-implantation-for-uveitis-and-uveitic-macular-edema
#18
Ashvini K Reddy, Bryn M Burkholder, Irfan R Khan, Jennifer E Thorne
No abstract text is available yet for this article.
October 13, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27630374/the-effect-of-different-dosing-schedules-of-intravitreal-sirolimus-a-mammalian-target-of-rapamycin-mtor-inhibitor-in-the-treatment-of-non-infectious-uveitis-an-american-ophthalmological-society-thesis
#19
RANDOMIZED CONTROLLED TRIAL
Quan Dong Nguyen, Mohammad Ali Sadiq, Mohamed Kamel Soliman, Aniruddha Agarwal, Diana V Do, Yasir J Sepah
PURPOSE: To determine if two different doses of intravitreal sirolimus, an mTOR inhibitor, can decrease inflammation and is safe in eyes with non-infectious posterior, intermediate, or panuveitis in the Sirolimus as a Therapeutic Approach UVEitis: Protocol-2 (SAVE-2) Study. METHODS: SAVE-2 is a prospective randomized, phase II, open-label interventional clinical trial conducted at 4 clinical centers in the United States. Eligible subjects were randomized into one of two treatments...
August 2016: Transactions of the American Ophthalmological Society
https://www.readbyqxmd.com/read/27598822/phacoemulsification-with-intraocular-lens-implantation-in-pediatric-uveitis-a-retrospective-study
#20
Sudha K Ganesh, Saurabh Mistry
PURPOSE: To analyze the outcome of phacoemulsification with primary posterior chamber intraocular lens (IOL) implantation without primary posterior capsulorhexis in older children with uveitis. METHODS: Retrospective study of children with uveitis who underwent phacoemulsification with IOL implantation between January 2006 and May 2014. RESULTS: Twenty-one eyes of 16 children were included. Mean age at cataract surgery was 10.9 years. Juvenile idiopathic arthritis was associated in 37...
September 6, 2016: Ocular Immunology and Inflammation
keyword
keyword
52850
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"